TRITIUM NMR ANALYSIS VT279 & VT286: CARDIOVASCULAR & PULMONARY DISEASE: SODIUM

受试化合物根据合同进行氚标记， Vitrax公司作为一家小型企业，Vitrax，Inc.缺乏资源， 对标记产品进行氚核磁共振分析。 这种核磁共振研究 以确定氚标记的位置和水平，作为最终的 为客户提供质量保证。 VT279是一个新的候选人 钠通道阻滞剂。 VT286是一种新的候选药物， 用于心血管和肺部疾病的评估。 仅氚和质子NMR分析。 用户详细信息： 详细信息：用户编号：1703 NMR市，州：Placentia，CA 1天 资金来源：工业2化合物费用：458.62美元计划收入： 458.62美元

The subject compounds were tritium labelled under contract at Vitrax, Inc. As a small business, Vitrax, Inc. lacks the resources to conduct tritium NMR analyses of labelled products. Such NMR studies serve to confirm the site and level of tritium labelling, as a final step in the quality assurance for customers. VT279 is a new candidate sodium channel blocker. VT286 is a new drug candidate under evaluation for cardiovascular and pulmonary disease applications. Tritium and proton NMR analyses only. User Details: Experiment Details: User Number: 1703 NMR City, State: Placentia, CA 1 day Funding Source: Industry 2 compounds Charge: $458.62 Program Income: $458.62